Cortexin Research Overview (also known as Cortexin 10, Polypeptides of Animal Brain Cortex, Cerebrolysin Alternative, Neuropeptide Bioregulator)
A polypeptide neuropeptide complex derived from porcine cerebral cortex tissue, manufactured by Geropharm in Russia. Cortexin contains a broad spectrum of low-molecular-weight neuropeptides including BDNF, NGF, CNTF, and GDNF, with over 30 years of clinical use across stroke, TBI, cognitive decline, and neurodevelopmental disorders. The most widely prescribed nootropic in Russia — frequently cited as a Cerebrolysin alternative offering IM-only administration.
What Is Cortexin?
Cortexin is a polypeptide neuropeptide complex derived from porcine (pig) cerebral cortex tissue, manufactured by Geropharm in Russia. Like Cerebrolysin, it contains a broad spectrum of low-molecular-weight neuropeptides including BDNF, NGF, CNTF, and GDNF, along with amino acids and microelements. It is the most widely used nootropic drug in Russia and Eastern Europe, with over 30 years of clinical use and multiple published clinical trials in stroke, TBI, cognitive decline, and childhood neurodevelopmental disorders. In research communities, it is frequently cited as a Cerebrolysin alternative — offering similar neuroprotective and neurorestorative mechanisms with the advantage of IM-only administration (no IV requirement).
Mechanism: Polypeptide Neuroprotection
Cortexin provides exogenous neuropeptides that cross the blood-brain barrier, modulate neurotransmitter levels, promote neuroplasticity, reduce oxidative stress in neuronal tissue, and regulate apoptosis. The mechanism is similar to Cerebrolysin but the specific peptide composition differs — Cortexin is derived from cerebral cortex while Cerebrolysin uses whole brain tissue. The 10 mg IM daily protocol used in research mirrors approved clinical protocols in Russia and Eastern Europe.
Comparison to Cerebrolysin
Cortexin and Cerebrolysin are the two most-studied polypeptide neuropeptide complexes. Key differences: Cortexin is IM-only (simpler administration), Cerebrolysin is IM or IV (IV enables higher dose delivery). Both are 10-day cycle compounds. Cerebrolysin has more published Western clinical trial data; Cortexin has a larger Eastern European clinical evidence base and is the more widely prescribed of the two in Russia. For practical research purposes, either can serve as a neurorestorative cycle compound — the choice often comes down to sourcing and preference for IM vs. IV administration.
Quick Reference
| Literature-Reported Dose Range | 10 mg IM daily (standard vial size) |
| Route | IM only (not for IV use) |
| Literature-Reported Cycle Length | 10 days — repeat 2–4× per year |
| Origin | Porcine cerebral cortex polypeptide complex |
| Classification | Cognitive & Mood / Neuropeptide Bioregulator |
| Clinical Status | Approved in Russia/Eastern Europe; RUO in Western markets |
Research Indications
Neurorestorative and neuroprotective research; post-stroke cognitive recovery; TBI recovery; age-related cognitive decline; neurodevelopmental disorders (extensive pediatric literature in Eastern Europe); general neuroplasticity enhancement in cognitive optimization protocols.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 10 mg | Once daily for 10 consecutive days | IM |
| Extended Protocol | 10 mg | Once daily for up to 20 days | IM |
Peptide Interactions
Both are polypeptide neuropeptide complexes with overlapping mechanisms. Combining them provides no meaningful additive benefit and unnecessarily doubles the exogenous neuropeptide load. Choose one per cycle.
Classic Eastern European cognitive stack — Cortexin provides the neuropeptide growth factor foundation while Semax drives BDNF/NGF expression. Used together in short Cortexin cycles layered within a Semax protocol.
NAD+ fuels the neuronal mitochondrial energy demands that Cortexin-driven neuroplasticity and repair require. A standard pairing in comprehensive cognitive optimization protocols.
Reported Research Timeline
Cortexin is administered as a 10-day intramuscular course with repeat cycles typically at 3–6 month intervals. Effects accumulate gradually through neurotrophic signaling rather than producing rapid onset; the research literature describes a characteristic course-to-course improvement trajectory across successive cycles.
- Days 1–3 (Onset): Plasma peptide fractions reach steady-state rapidly; however, downstream neurotrophic effects — BDNF, NGF, and GDNF upregulation — require several days of cumulative signaling to manifest. Mild improvements in focus or sleep architecture may appear early.
- Days 4–10 (Peak Course Window): The primary therapeutic window. Published clinical research in post-stroke and age-related cognitive decline models reports measurable improvements in memory consolidation, processing speed, and cognitive flexibility by the final days of the injection series.
- Weeks 2–4 (Post-Course Persistence): Neurotrophic factor upregulation outlasts the final injection by several weeks. BDNF elevation, synaptic remodeling, and cognitive improvements continue during this period — which is why most published protocols assess outcomes at the 2-week post-course mark rather than immediately after the last dose.
- Months 1–3 (Inter-Course Window): Effects taper gradually, but a subset of benefits — particularly in subjects with structural neurological insults or significant baseline cognitive impairment — appears to persist longer. Researchers tracking repeat-course outcomes often observe cumulative gains across successive cycles.
- Months 3–6 (Repeat Course Consideration): Published Russian and Eastern European clinical literature uses 3-to-6-month inter-course intervals. Annual exposure of 2–4 full courses is the most commonly studied cadence for cognitive aging and neurological rehabilitation applications.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Derived from porcine brain tissue. Individuals with pork allergies or religious dietary restrictions should not use. Theoretical (not documented) prion disease risk exists with any CNS-derived animal product, though no cases have been reported in Cortexin's clinical history.
IM only — do not attempt IV administration. Not formulated for intravenous use.
Injection site soreness is common with daily IM injections. Rotate between gluteal and thigh sites. Use a 25–27 gauge needle for minimal tissue trauma.
Not approved by the FDA. Primarily used in Russia, Ukraine, and Eastern European clinical settings. Western sourcing is typically from Eastern European suppliers — verify product authenticity and cold-chain integrity.
Seek Medical Attention If:
New or worsening neurological symptoms (seizures, significant confusion, or vision changes)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Persistent injection site pain or swelling beyond 48 hours
Always consult a licensed physician before and during use
Quality Indicators
Verified
Authentic Manufacture
Genuine Cortexin is manufactured by Geropharm (Russia). Authentic product bears Russian registration markings and foil-sealed vials.
Expected
Cold Chain Integrity
Cortexin lyophilized powder must be stored at 2–8°C. Verify cold-chain documentation through shipping; reject products with temperature breaks.
Expected
Lot Number & CoA
Authentic Russian-sourced Cortexin should include a lot number traceable to the original manufacturer certificate of analysis.
Red Flag
Non-Pharma Research Supplier Source
Cortexin is a licensed pharmaceutical — it should NOT be sourced from generic peptide RUO suppliers. Pharmaceutical-grade vials only.
Research Citations
Frequently Asked Questions
What should researchers watch for with Cortexin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Cortexin?
Cortexin is administered as a 10-day intramuscular course with repeat cycles typically at 3–6 month intervals. Effects accumulate gradually through neurotrophic signaling rather than producing rapid onset; the research literature describes a characteristic course-to-course improvement trajectory across successive cycles.
How is Cortexin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →